LOS ANGELES, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology company developing a universal, off-the-shelf, gene-enhanced antigen-presenting cell therapy platform, today announced the ...
Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results